Use of preservative-free hyaluronic acid (Hylabak^®) for a range of patients with dry eye syndrome: experience in Russia

Figures & data

Table 1 Patient characteristics and methodologic summary of four open studies of Hylabak^® in patients with dry eye syndrome

Reference	n	Dry eye etiology	Treatment	Assessments
Maychuk and Yani^Citation24	40	Adenovirus eye infection, 18; soft contact lens use, 10; phacoemulsification with intraocular lens implantation, 7; refractive surgery, 5	Hylabak 3–4 times daily for 28 days. Assessments on days 1, 7, 14, 21, and 28	Subjective complaints, Schirmer’s test, Norn’s test, meniscometry, osmometry, conjunctival xerosis
Brjesky et al^Citation25	32a	Postmenopausal women with mild/moderate deficiency of tear film production, 12; persistent meibomian blepharitis, 10;b Sjögren’s syndrome, 10	Hylabak four times daily for 28 days. Assessments on days 3, 7, 14 and 28	Subjective discomfort, Schirmer’s test, tear meniscus index, Norn’s test, basal and total tear production
Petrayevsky et al^Citation26	32	Intensive work with computers in air-conditioned offices (18 menopausal)	Hylabak twice daily for 2 weeks. Assessments performed before and after treatment	Subjective complaints, Schirmer’s test, Norn’s test, cytologic analysis of bulbar conjunctiva
Nagorsky et al^Citation27	30	Soft contact lens use during the daytime, 20; orthokeratologic lens use at night with signs of epitheliopathy and sticking, 10	One drop Hylabak 3–5 times daily in soft contact lens wearers and use for several minutes before and after removing lenses in orthokeratologic lens wearers for 2 months. Assessments performed at baseline and after 1 and 2 months	Subjective sensations, Schirmer’s test, Norn’s test, meniscometry, conjunctival xerosis

Note:

a Compared with 25 patients treated with Tear Naturale^® in previous studies;²⁸

b 18 eyes.

Table 2 Etiology of dry eye syndrome in each study

	Adenovirus infection	Soft contact lenses	Refractive surgery	Phacoemulsification	Menopause	Meibomian blepharitis	Sjögren’s syndrome	Adolescent soft contact lens users
Maychuck and Yani^Citation24	18	10	5	7
Brjesky et al^Citation25					22	20	15
Petrayevsky et al^Citation26					32
Nagorsky et al^Citation27								20

Figure 1 Change in subjective discomfort score during 28 days of treatment with Hylabak^® in (A) postmenopausal women, (B) patients with persistent meibomian blepharitis, and (C) Sjögren’s syndrome (n=32)²⁵ compared with a similar group of patients treated with Tear Naturale^® (n=25).²⁸

Note: *P<0.05 versus baseline.

Figure 2 Change in objective signs score during 28 days of treatment with Hylabak^® in (A) postmenopausal women, (B) patients with persistent meibomian blepharitis, and (C) Sjögren’s syndrome (n=32)²⁵ compared with a similar group of patients treated with Tear Naturale^® (n=25).²⁸

Note: *P<0.05 versus baseline.

Figure 3 Change in subjective signs and symptoms score during 2 weeks of treatment with Hylabak^® in office workers with (A) mild or (B) moderate symptoms (n=32).²⁶

Figure 4 Change in number of patients with subjective complaints during 2 months of treatment with Hylabak^® in children and adolescents wearing soft contact lenses (n=20).²⁷

Table 3 Results of functional tests (Schirmer’s test and Norn’s test) performed in all four studies

	Day 1		Day 7		Day 14		Day 21		Day 28
	Mild (n=20)	Moderate (n=20)	Mild (n=20)	Moderate (n=20)	Mild (n=20)	Moderate (n=20)	Mild (n=20)	Moderate (n=20)	Mild (n=20)	Moderate (n=20)
Maychuk and Yani^Citation24
Schirmer’s test (mm)	5.8 ± 1.7	3.7 ± 1.0	6.2 ± 1.2	3.9 ± 1.3	7.4 ± 1.5	4.7 ± 1.6	7.9 ± 1.4	5.4 ± 1.5	8.3 ± 1.5	6.4 ± 1.3
Norn’s test (seconds)	5.6 ± 1.0	3.1 ± 1.2	6.2 ± 1.1	3.9 ± 1.5	7.4 ± 0.9	4.0 ± 1.0	8.7 ± 1.5	4.9 ± 0.9	9.6 ± 1.5	6.7 ± 1.3
	Baseline		Day 3		Day 7		Day 14		Day 28
	Hylabak^®	Tear Naturale^®	Hylabak	Tear Naturale	Hylabak	Tear Naturale	Hylabak	Tear Naturale	Hylabak	Tear Naturale
Brjesky et al^Citation25
Postmenopausal women	(n=12)	(n=10)	(n=12)	(n=10)	(n=12)	(n=10)	(n=12)	(n=10)	(n=12)	(n=10)
Norn’s test (seconds)	7.1 ± 0.3	7.0 ± 0.4	9.0 ± 0.3*	8.7 ± 0.3*	10.2 ± 0.4*	9.7 ± 0.5*	10.4 ± 9.4*	9.4 ± 0.6*	10.1 ± 0.5*	9.7 ± 0.6*
Meibomian blepharitis	(n=10)	(n=10)	(n=10)	(n=10)	(n=10)	(n=10)	(n=10)	(n=10)	(n=10)	(n=10)
Norn’s test (seconds)	5.3 ± 0.2	5.4 ± 0.2	6.5 ± 0.3*	6.3 ± 0.5	8.1 ± 0.4*	7.7 ± 0.2*	8.8 ± 0.4*	8.4 ± 0.3*	8.7 ± 0.4*	8.3 ± 0.3*
Sjögren’s syndrome	(n=10)	(n=5)	(n=10)	(n=5)	(n=10)	(n=5)	(n=10)	(n=5)	(n=10)	(n=5)
Norn’s test (seconds)	3.5 ± 0.3	3.4 ± 0.3	5.2 ± 0.2*	5.0 ± 0.3*	5.6 ± 0.2*	5.5 ± 0.3*	5.5 ±0.1*	5.6 ± 0.2*	5.5 ±0.1*	5.7 ± 0.3*
	Baseline		2 weeks
	Mild (n=18)	Moderate (n=14)	Mild (n=18)	Moderate (n=14)
Petrayevsky et al^Citation26
Schirmer’s test (mm) mean	23.44 ± 9.01	5.14 ± 2.40	18.83 ± 6.48	10.96 ± 3.04**
Norn’s test (seconds) (mean)	10.04 ± 3.18	7.79 ± 3.44	24.58 ± 9.27**	22.34 ± 12.38**
	Baseline (n=20)	1 month (n=20)	2 months (n=20)
Nagorsky et al^Citation27,a
Schirmer’s test (mm)	11.10 ± 4.62	10.12 ± 4.13	10.38 ± 3.65
Norn’s test (seconds)	8.07 ± 3.28	10.13 ± 2.85	11.52±3.11*

Notes:

* P<0.05 versus baseline;

** P<0.01 versus baseline.

a Results from patients with soft contact lenses.

MaychukYFYaniEVNew hyaluronic-acid-based artificial tear drug Hylabak for dry eye therapyJ Cataract Refract Surg2011114850

 Google Scholar

BrjeskyVVProzornayaLPSadovnikovaNNRadhuanMRNew preservative-free hyaluronic acid preparations in treatment of patients with dry eye syndromeOcular Pharmacology Issues2011IV299104 Russian

 Google Scholar

PetrayevskyAVTrishkinKSLyovinaOVThe dry eye syndrome in female office workers: a clinical and cytological analysis of results of treatment with HylabakRussian Ophthalmological Journal201224953

 Google Scholar

NagorskyPGBelkinaVVNesterovaLYEffect of tear-replacement therapy (Hylabac 0.15%) on the dry-eye syndrome intensity in children and adolescents wearing contact lensesRussian Ophthalmology Journal201123236

 Google Scholar

BrjeskyVVProzornayaLPNew artificial tear preparation Ophtholique in treating patients with dry eye syndrome of different genesisOphthalmological Journal2009II6368 Russian

 Google Scholar